ArticleAdvances in experimental medicine and biology2017
Tumor Immuno-Environment in Cancer Progression and Therapy.
Article in Advances in experimental medicine and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- NOD1/2 signaling in macrophages drives adaptive immune resistance in cancer.Signal transduction and targeted therapy · 2026Article
- Elevated Interleukin-1β and Deep Tissue Cryptosporidium Infection in Colorectal Cancer: A Novel Association.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy?Gene therapy · 2025Review
- CLEC11A as a potential biomarker for prognosis and response to immunotherapy in colon adenocarcinoma.Discover oncology · 2025Article
- Divergent roles of PKM2 in regulating PD-L1 and PD-L2 expression and their implications in human and mouse cancer models.Acta biochimica et biophysica Sinica · 2025Article
- Article
- CC chemokine receptors are prognostic indicators of gastric cancer and are associated with immune infiltration.BMC medical genomics · 2024Article
- Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.European journal of nuclear medicine and molecular imaging · 2023Article
- A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer.Journal for immunotherapy of cancer · 2023Article
- PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.Scientific reports · 2023Article
- Poor Prognostic Biomarker KIAA1522 Is Associated with Immune Infiltrates in Hepatocellular Carcinoma.Journal of oncology · 2023Article
- Type 1 interferon mediated signaling is indispensable for eliciting anti-tumor responses byFrontiers in immunology · 2023Article
- MYL5 as a Novel Prognostic Marker is Associated with Immune Infiltrating in Breast Cancer: A Preliminary Study.The breast journal · 2023Article
- Identification ofBreast cancer (Dove Medical Press) · 2023Article
- AMICA1 is a diagnostic and prognostic biomarker and induces immune cells infiltration by activating cGAS-STING signaling in lung adenocarcinoma.Cancer cell international · 2022Article
- ES-MION-Based Dual-Modality PET/MRI Probes for Acidic Tumor Microenvironment Imaging.ACS omega · 2022Article
- Understanding the tumor microenvironment in head and neck squamous cell carcinoma.Clinical & translational immunology · 2022Review
- Diagnostic Value, Prognostic Value, and Immune Infiltration ofFrontiers in oncology · 2022Article
- Development and validation of a novel immunotype for prediction of overall survival in patients with clear cell renal cell carcinoma.Frontiers in oncology · 2022Article
- Systemic Interleukins' Profile in Early and Advanced Colorectal Cancer.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The approvals of Provenge (Sipuleucel-T), Ipilimumab (Yervoy/anti-CTLA-4) and blockers of the PD-1 - PD-L1/PD-L2 pathway, such as nivolumab (Opdivo), pembrolizumab (Keytruda), or atezolizumab (Tecentriq), have established immunotherapy as a key component of comprehensive cancer care. Further, murine mechanistic studies and studies in immunocompromised patients have documented the critical role of immunity in effectiveness of radio- and chemotherapy. However, in addition to the ability of the immune system to control cancer progression, it can also promote tumor growth, via regulatory T cells (Tregs), myeloid-derived dendritic cells (MDSCs) and tumor associated macrophages (TAM), which can enhance survival of cancer cells directly or via the regulation of the tumor stroma.An increasing body of evidence supports a central role for the tumor microenvironment (TME) and the interactions between tumor stroma, infiltrating immune cells and cancer cells during the induction and effector phase of anti-cancer immunity, and the overall effectiveness of immunotherapy and other forms of cancer treatment. In this chapter, we discuss the roles of key TME components during tumor progression, metastatic process and cancer therapy-induced tumor regression, as well as opportunities for their modulation to enhance the overall therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.